GLP-1 Agonists: Less Weight Loss, Possible Breast Cancer Survival

Obesity is a recognised risk factor for several cancers, including breast cancer, and is associated with poorer prognoses. Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of prescription therapy widely used for type 2 diabetes and weight management. Their mechanism of action involves glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction. While their primary indications are metabolic, preclinical and observational studies have explored their potential pleiotropic effects, including those relevant to oncology.

Emerging Data on GLP-1 Agonists and Breast Cancer

The hypothesis linking GLP-1 agonists to improved cancer outcomes stems from several biological pathways. GLP-1 receptors are expressed in various tissues beyond the pancreas and gut, including some cancer cells. Activation of these receptors may influence cellular proliferation, apoptosis, and inflammation, all of which are relevant to carcinogenesis and tumour progression. Additionally, the weight loss and metabolic improvements achieved with GLP-1 agonists could indirectly benefit cancer patients by reducing obesity-related inflammation and insulin resistance, which are known drivers of tumour growth.

Observational studies have begun to investigate the association between GLP-1 agonist use and breast cancer outcomes. These studies typically analyse large healthcare databases to compare outcomes in patients with type 2 diabetes who are prescribed GLP-1 agonists versus those prescribed other antidiabetic medications. One such analysis, examining a cohort of patients with type 2 diabetes and a history of breast cancer, found a potential association between GLP-1 agonist use and improved breast cancer-specific survival. The hazard ratio (HR) for breast cancer-specific mortality in GLP-1 agonist users compared to non-users was reported to be approximately 0.75 (95% CI: 0.60-0.94), with a p-value of 0.01. This suggests a 25% reduction in the risk of breast cancer-specific mortality in patients using GLP-1 agonists. However, it is important to note that these studies are observational and cannot establish causality. Confounding by indication and other unmeasured factors remain potential limitations.

The patient populations in these observational studies often consist of individuals with established type 2 diabetes, a condition itself associated with an increased risk of various cancers, including breast cancer. The presence of diabetes can complicate cancer treatment and prognosis, making interventions that address both conditions particularly relevant. The specific cohort examined in the aforementioned analysis included patients who had already received a breast cancer diagnosis, allowing for an evaluation of GLP-1 agonist use in a secondary prevention or adjuvant setting. Researchers typically employ propensity score matching or other statistical methods to balance baseline characteristics between GLP-1 agonist users and non-users, aiming to mitigate confounding factors such as age, duration of diabetes, body mass index, and other comorbidities. Despite these efforts, residual confounding is a persistent challenge in observational research.

Regarding weight loss, while GLP-1 agonists are effective for weight management, the degree of weight loss observed in patients with concurrent breast cancer may vary. In populations specifically studied for oncology outcomes, the primary focus has been on survival endpoints rather than maximal weight reduction. The observed survival benefits, if confirmed, may not be solely dependent on the magnitude of weight loss but could also be attributed to direct anti-tumour effects or other metabolic improvements. For instance, reductions in systemic inflammation markers and improvements in insulin sensitivity, even with modest weight loss, could contribute to a more favourable tumour microenvironment.

Further exploration into the direct mechanisms by which GLP-1 agonists might exert anti-tumour effects involves investigating their influence on cellular signaling pathways critical for cancer cell survival and proliferation. Studies suggest GLP-1 receptor activation can modulate pathways such as mTOR, MAPK, and PI3K/Akt, which are frequently dysregulated in breast cancer. Additionally, GLP-1 agonists may impact the tumour microenvironment by altering immune cell function or reducing angiogenesis. These direct cellular effects, combined with systemic metabolic improvements, offer a multifaceted explanation for the observed associations.

Current evidence does not support the routine prescription of GLP-1 agonists solely for breast cancer prevention or treatment. The data, while intriguing, are primarily derived from retrospective analyses and require validation through prospective, randomised controlled trials. These trials would be designed to specifically evaluate the impact of GLP-1 agonists on breast cancer recurrence, progression-free survival, and overall survival in defined patient populations. Such studies would also provide clearer insights into the optimal dosing, duration of therapy, and patient subgroups most likely to benefit.